Table 3.
Marginal utilities and willingness to pay (WTP)—preferences of people with lived experience of acute care genomics.
| Attributes | Mean | Std. deviation | Importance score, % | Marginal WTP, AU$ (95% CIs) |
|---|---|---|---|---|
| Number of children who receive genetic diagnosis (out of 100) | 0.03186*** | 0.02370*** | 21 | 75 (36–113) |
| Time between test initiation and results (12 weeks)a | −0.10734 | 0.18389 | 14 | – |
| Time between test initiation and results (2 weeks)a | 1.31794*** | 0.03411 | 3120 (1393–4800) | |
| Time between test initiation and results (2 days)a | 1.44781*** | 0.78912 | 3427 (1483–5322) | |
| Chance of improving the process of child’s medical care (%) | 0.03786*** | 0.00036 | 21 | 90 (53–125) |
| Chance of improving child’s health outcomes (%) | 0.14079* | 0.20330*** | 13 | 334 (1–661) |
| Cost of testing to you (AU$) | −0.00043*** | 0.00018*** | 31b | |
| Genomic testing constant | 2.13200 | 1.54158 | ||
| Log likelihood function | −200.44 | |||
| McFadden Pseudo R2 | 0.39 | |||
| Akaike information criterion | 432.9 | |||
Marginal utilities indicate the marginal effect of each attribute (or attribute level) on the utility for genomic testing. Positive (or negative) mean estimates indicate, on average, a positive (or negative) effect on utility. Standard deviation estimates describe the heterogeneity of preferences among study participants. Marginal WTP estimates represent the marginal rate of substitution between the corresponding attribute and the cost attribute.
*Statistically significant at 10% level.
***Statistically significant at 1% level.
aMarginal utilities and values are relative to the base level of 6 months.
bRanged over AU$450–8100. The values correspond to the 0.5% and 10% cost attribute levels with the income adjustment.